These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26299420)

  • 21. Cellular features of psoriatic skin: imaging and quantification using in vivo reflectance confocal microscopy.
    Wolberink EA; van Erp PE; Teussink MM; van de Kerkhof PC; Gerritsen MJ
    Cytometry B Clin Cytom; 2011 May; 80(3):141-9. PubMed ID: 21520401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis and its treatment with adalimumab.
    Iaconi A; Feldman SR; Balkrishnan R
    Expert Opin Biol Ther; 2010 Jan; 10(1):133-52. PubMed ID: 20078231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab: A Review in Chronic Plaque Psoriasis.
    Burness CB; McKeage K
    Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
    Menting SP; van Lümig PP; de Vries AC; van den Reek JM; van der Kleij D; de Jong EM; Spuls PI; Lecluse LL
    JAMA Dermatol; 2014 Feb; 150(2):130-6. PubMed ID: 24352354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo imaging techniques for psoriatic lesions.
    Căruntu C; Boda D; Căruntu A; Rotaru M; Baderca F; Zurac S
    Rom J Morphol Embryol; 2014; 55(3 Suppl):1191-6. PubMed ID: 25607405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients.
    Ardigò M; Giuliani A; de Felice C; Mastroianni A; Berardesca E
    J Drugs Dermatol; 2008 Oct; 7(10):935-9. PubMed ID: 19112756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement.
    Soegaard-Madsen L; Johansen C; Iversen L; Kragballe K
    Br J Dermatol; 2010 Jun; 162(6):1216-23. PubMed ID: 20346019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
    Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
    J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Toll-like receptors in psoriatic patients during therapy with adalimumab.
    De Pita O; Nardis C; Lupi F; Luci CA; Frezzolini A; Pallotta S
    Int J Immunopathol Pharmacol; 2011; 24(1):185-8. PubMed ID: 21496401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
    Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
    Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-α treatment.
    Renzo LD; Saraceno R; Schipani C; Rizzo M; Bianchi A; Noce A; Esposito M; Tiberti S; Chimenti S; DE Lorenzo A
    Dermatol Ther; 2011; 24(4):446-51. PubMed ID: 21910803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.
    Bissonnette R; Tardif JC; Harel F; Pressacco J; Bolduc C; Guertin MC
    Circ Cardiovasc Imaging; 2013 Jan; 6(1):83-90. PubMed ID: 23204039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.